Complete blood counts (CBCs) with plateletcount and serum chemistries should be performed at the beginning of eachtreatment cycle for patients receiving treatment with Sutent. The most common adverse reactions in advanced RCC and GIST clinical trials werefatigue, asthenia, diarrhea, nausea, mucositis/stomatitis, vomiting, dyspepsia,abdominal pain, constipation, hypertension, rash, hand-foot syndrome, skindiscoloration, altered taste, anorexia and bleeding. For more information on Sutent and Pfizer Oncology, including full prescribinginformation for Sutent (sunitinib malate), please visit About Aromasin (exemestane tablets)Aromasin is the only aromatase inhibitor indicated for sequential therapy inpostmenopausal women with HR positive early breast cancer after 2-3 years oftamoxifen for a total of 5 years of adjuvant therapy. The use of Aromasin inthis setting is supported by the landmark IES trial. Aromasin is also indicatedfor the treatment of advanced breast cancer in postmenopausal women whosedisease has progressed following tamoxifen therapy.

Important Aromasin (exemestane tablets) Safety InformationAromasin should not be used in women who are premenopausal, are nursing orpregnant, have a known hypersensitivity to the drug, or are takingestrogen-containing agents. Dose modification is recommended for patients whoare receiving certain medications, including strong CYP 3A4 inducers. Inpatients with early breast cancer, elevations in bilirubin, alkalinephosphatase, and creatinine were more common in those receiving Aromasin thaneither tamoxifen or placebo. About Camptosar(irinotecan HCI injection)Camptosar is indicated as a component of 1st line therapy in combination with5-FU/LV for the treatment of metastatic colorectal cancer. Camptosar is alsoindicated for patients with mCRC whose disease has recurred or progressedfollowing initial FU-based therapy. Important Camptosar (irinotecan HCI injection) Safety InformationWith Camptosar, both early and late forms of diarrhea can occur and may be lifethreatening.

Late diarrhea should be managed promptly with loperamide andsupportive care including antibiotics as needed Camptosar can induce severemyelosuppression. Depending on the severity of neutropenia, dose delay, dosereduction, or use of a colony-stimulating factor should be considered. Particular caution should be exercised in monitoring the effects of Camptosar inthe elderly (>65), in patients who have previously received pelvic/abdominalirradiation, in patients with performance status of 2 or higher, and in patientsknown to be homozygous for the UGT1A1*28 allele. Rare cases of ileus,complicated colitis, or renal impairment have been observed. It is recommendedthat patients receive premedication with antiemetic agents. Prophylactic ortherapeutic administration of atropine should be considered in patientsexperiences cholingeric symptoms.

Provided intolerable toxicity does notdevelop, treatment with additional courses may be continued indefinitely as longas patients continue to experience clinical benefits. Thromboembolic events havebeen observed but the specific cause has not been determined. Camptosar shouldnot be used in patients with severe bone marrow failure. Vaccination with a livevaccine should be avoided in patients receiving irinotecan due to the potentialfor serious fatal infections. In addition, patients with hereditary fructoseintolerance should not be given Camptosar, as this product contains sorbitol. DISCLOSURE NOTICE: The information contained in this release is as of May 13,2009. Pfizer assumes no obligation to update any forward-looking statementscontained in this release as the result of new information or future events ordevelopments.This release contains forward-looking information about various oncology productcandidates and potential additional indications for Sutent, including theirpotential benefits, as well as certain prognostic and predictive factors whichmay help identify patients who may be most likely to benefit from varioustreatments, that involves substantial risks and uncertainties.

Such risks anduncertainties include, among other things, the uncertainties inherent inresearch and development; decisions by regulatory authorities regarding whetherand when to approve any drug applications that may be filed for any such productcandidates or any such additional indications for Sutent as well as theirdecisions regarding labeling and other matters that could affect theiravailability or commercial potential; and competitive developments.A further description of risks and uncertainties can be found in Pfizer`s AnnualReport on Form 10-K for the fiscal year ended December 31, 2008 and in itsreports on Form 10-Q and Form 8-K.PfizerMedia:Jack Cox, 212-733-5017orInvestors:Jennifer Davis, 212-733-0717 Copyright Business Wire 2009. DUBLIN--(Business Wire)--Research and Markets( http://) hasannounced the addition of the "Booming Russian Automobile Sector" report totheir offering. According to our new research report - "Booming Russian Automobile Sector" - theRussian automotive industry is growing at a fast pace and emerging as one of themost competitive and dynamic industries at the world level. Governmentinitiatives and incentives are filliping the industry and attracting the foreignplayers to the market.